Literature DB >> 9003853

Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency with the G1528C mutation: clinical presentation of thirteen patients.

T Tyni1, A Palotie, L Viinikka, L Valanne, M K Salo, U von Döbeln, S Jackson, R Wanders, N Venizelos, H Pihko.   

Abstract

Long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase is one of three enzyme activities of the mitochondrial trifunctional protein. We report the clinical findings of 13 patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. At presentation the patients had had hypoglycemia, cardiomyopathy, muscle hypotonia, and hepatomegaly during the first 2 years of life. Seven patients had recurrent metabolic crises, and six patients had a steadily progressive course. Two patients had cholestatic liver disease, which is uncommon in beta-oxidation defects. One patient had peripheral neuropathy, and six patients had retinopathy with focal pigmentary aggregations or retinal hypopigmentation. All patients were homozygous for the common mutation G1528C. However, the enoyl-CoA hydratase and 3-ketoacyl-CoA thiolase activities of the mitochondrial trifunctional protein were variably decreased in skin fibroblasts. Dicarboxylic aciduria was detected in 9 of 10 patients, and most patients had lactic acidosis, increased serum creatine kinase activities, and low serum carnitine concentration. Neuroradiologically there was bilateral periventricular or focal cortical lesions in three patients, and brain atrophy in one. Only one patient, who has had dietary treatment for 9 years, is alive at the age of 14 years; all others died before they were 2 years of age. Recognition of the clinical features of long-chain 3-hydroxyacyl-CoA deficiency is important for the early institution of dietary management, which may alter the otherwise invariably poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9003853     DOI: 10.1016/s0022-3476(97)70312-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  35 in total

1.  Neonatal diagnosis of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and implications for newborn screening by tandem mass spectrometry.

Authors:  K H Carpenter; B Wilcken
Journal:  J Inherit Metab Dis       Date:  1999-10       Impact factor: 4.982

Review 2.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

3.  Absence of G1528C mutation in long-chain 3-hydroxyacyl-CoA dehydrogenase in four Indian patients with pregnancy-related liver disease.

Authors:  V Raghupathy; Ashish Goel; Kavitha R Thangaraj; C E Eapen; K A Balasubramanian; Annie Regi; Ruby Jose; Santosh J Benjamin; Anup Ramachandran
Journal:  Indian J Gastroenterol       Date:  2014-07

Review 4.  Neonatal onset in fatty acid oxidation disorders: how can we minimize morbidity and mortality?

Authors:  E Riudor
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

5.  L-3-hydroxyacyl-CoA dehydrogenase deficiency: two cases with pigmentary retinopathy.

Authors:  J Uusimaa; L Vainionpää; S Similä; R Miettinen; M Nuutinen
Journal:  J Inherit Metab Dis       Date:  1997-11       Impact factor: 4.982

6.  Growth in Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency.

Authors:  C Bieneck Haglind; M Halldin Stenlid; S Ask; J Alm; A Nemeth; Uv Döbeln; A Nordenström
Journal:  JIMD Rep       Date:  2012-07-06

7.  Cholestatic Jaundice Associated with Carnitine Palmitoyltransferase IA Deficiency.

Authors:  A A M Morris; S E Olpin; M J Bennett; A Santani; J Stahlschmidt; P McClean
Journal:  JIMD Rep       Date:  2012-03-21

Review 8.  Mitochondrial deficiency in Cockayne syndrome.

Authors:  Morten Scheibye-Knudsen; Deborah L Croteau; Vilhelm A Bohr
Journal:  Mech Ageing Dev       Date:  2013-02-19       Impact factor: 5.432

9.  Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders.

Authors:  J J Shen; D Matern; D S Millington; S Hillman; M D Feezor; M J Bennett; M Qumsiyeh; S G Kahler; Y T Chen; J L Van Hove
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

10.  ERRgamma regulates cardiac, gastric, and renal potassium homeostasis.

Authors:  William A Alaynick; James M Way; Stephanie A Wilson; William G Benson; Liming Pei; Michael Downes; Ruth Yu; Johan W Jonker; Jason A Holt; Deepak K Rajpal; Hao Li; Joan Stuart; Ruth McPherson; Katja S Remlinger; Ching-Yi Chang; Donald P McDonnell; Ronald M Evans; Andrew N Billin
Journal:  Mol Endocrinol       Date:  2009-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.